Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
63 hedge funds and large institutions have $152M invested in Viracta Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 14 closing their positions.
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
65% more capital invested
Capital invested by funds: $92M → $152M (+$59.9M)
26% more funds holding
Funds holding: 50 → 63 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
8% less call options, than puts
Call options by funds: $885K | Put options by funds: $961K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$18.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.86M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.92M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.72M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.35M |
| 3 |
Goldman Sachs
New York
|
-$3.44M |
| 4 |
Janus Henderson Group
London,
|
-$3.34M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.53M |
VIRX Hedge Fund Activity: Q2 2021 in Review
63 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2021, worth a combined $152M — up 65% from $92M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new VIRX positions and 14 closed out — a net gain of 13 holders — while 12 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $18.8M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $4.72M sold.
- 63 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2021, up from 50 in Q1 2021.
- Funds reported $152M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2021, up 65% quarter-over-quarter.
- 27 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2021 and 14 closed out, a net change of +13 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $18.8M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2021 was T. Rowe Price Associates, an estimated $4.72M sold.
Based on aggregated 13F filings for Q2 2021.